A federal judge has handed Pfizer an important evidentiary ruling in the long-running antitrust case over its epilepsy drug Neurontin.

While denying summary judgment to both sides, U.S. District Judge Faith Hochberg refused to bar evidence of settlements Pfizer has received in infringement suits against generic drug makers.